NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Oruka Therapeutics, Inc. ORKA
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-22.3%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 18-year series below
Revenue
Net income
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-22.3%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-21.6%
Each USD of equity lost 22 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 488.6M
total assets, end of FY2025
Total assetsUSD 488.6M
EquityUSD 471.9M
CashUSD 46.9M
Current ratio22.37×
Equity funds 97% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.1
·
·
·
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
·
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−22.3
−13.6
−21.4
−39.6
−36.0
−80.4
−97.3
−113.9
−54.6
−43.3
−63.9
−75.1
−100.0
−85.8
−118.7
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed